Physician profile
Anna Z Madej
NPI 1194834705
$6,200.62
in general payments reported to CMS, 2019-2025
37 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $365 · 2021: $664 · 2022: $991 · 2023: $1,358 · 2024: $1,064 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,455.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $983.15 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Abbvie INC. | $602.22 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $562.53 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.11 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $461.73 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $421.51 | 2019-2025 | |
| Novo Nordisk INC | $406.56 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $328.46 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $207.68 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $184.89 | 2021-2022 | |
| Electromed, INC. | $153.67 | 2022-2023 | Smartvest |
| Lilly USA, LLC | $141.91 | 2019-2025 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $139.74 | 2023-2025 | Rexulti |
| Dexcom, INC. | $134.52 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $128.66 | 2021-2023 | Trelegy Ellipta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $125.26 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $118.35 | 2023-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $77.18 | 2019-2023 | Myrbetriq, Veozah |
| Mylan Specialty L.P. | $64.07 | 2019-2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $62.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $55.46 | 2021-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| E.R. Squibb & Sons, L.L.C. | $51.59 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.30 | 2025 | Xifaxan |
| Cmp Pharma, INC. | $31.01 | 2021 | |
| Phathom Pharmaceuticals, INC. | $30.55 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $29.02 | 2021 | |
| Alk-Abello, INC | $24.34 | 2024 | Grastek, Odactra, Ragwitek |
| Lundbeck LLC | $20.84 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $20.65 | 2025 | Injectafer |
| Ironwood Pharmaceuticals, INC | $19.48 | 2020 | |
| Baxter Healthcare | $18.43 | 2025 | Hillrom - Synclara Cough System |
| Genentech USA, INC. | $18.30 | 2020 | |
| Sobi, INC | $15.52 | 2019 | |
| Eisai INC. | $15.24 | 2021 | |
| Becton, Dickinson and Company | $13.65 | 2021 | |
| Abbott Laboratories | $13.21 | 2022 | |
| Tactile Systems Technology INC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Madej listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.